Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
Edwards Lifesciences (EW) Stock Price & Analysis
1,647 Followers
EW Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$60.57 - $96.12
Previous Close$86.43
Volume3.10M
Average Volume (3M)4.02M
Market Cap
$51.97B
Enterprise Value$51.09B
Total Cash (Recent Filing)$1.64B
Total Debt (Recent Filing)$694.90M
Price to Earnings (P/E)37.2
Beta1.20
Next Earnings
Jul 25, 2024EPS Estimate
$0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.32
Shares Outstanding601,300,000
10 Day Avg. Volume3,304,469
30 Day Avg. Volume4,023,015
Standard Deviation0.09
R-Squared0.40
Alpha-0.00181
Financial Highlights & Ratios
Price to Book (P/B)10.46
Price to Sales (P/S)8.61
Price to Cash Flow (P/CF)117.70
P/FCF Ratio245.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.51
Enterprise Value/Gross Profit11.05
Enterprise Value/Ebitda28.74
Forecast
1Y Price Target
$95.80Price Target Upside13.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering23
Edwards Lifesciences News
Bulls Say, Bears Say
Bulls Say
Company PerformanceSolid financial performance is indicated by the company's raised guidance for sales growth, driven by strong market adoption and the successful performance of TMTT and Critical Care segments.
Market PotentialAnalyst checks suggest a premium pricing strategy for the newly approved Evoque TTVR system, reflecting a strong market opportunity and the potential to generate significant revenue.
Product ApprovalThe Evoque TTVR system's recent FDA approval brings a new, innovative treatment option to the market, addressing the needs of patients with severe aortic stenosis.
Bears Say
Clinical Trial ResultsSmart trial reported a 20% paravalvular leak rate for Sapien 3, which is higher than the 10-12% rates observed in real-world registries such as the TVT registry.
Earnings GuidanceQ2 EPS guidance midpoint is below prior consensus.
Market Share And Sales VolumeSurvey suggests modest deceleration of U.S. TAVR volumes in 2024 and 2025, with market share erosion expected for EW.
---
Ownership Overview
1.06% Insiders
22.89% Mutual Funds
22.88% Other Institutional Investors
53.16% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EW FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was $60.57 and its highest was $96.12 in the past 12 months.
What is Edwards Lifesciences’s market cap?
Currently, no data Available
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Jul 25, 2024 which is in 82 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Apr 25, 2024. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.643 by $0.017.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is $0.7.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 601,300,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of $0.66 in its last earnings report, beating expectations of $0.643. Following the earnings report the stock price went down -1.795%.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Among the largest hedge funds holding Edwards Lifesciences’s share is Fisher Asset Management LLC. It holds Edwards Lifesciences’s shares valued at 544M.
---
Edwards Lifesciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$95.80 (13.15% Upside)
$95.80 (13.15% Upside)
Blogger Sentiment
Bullish
EW Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.30%
12-Months-Change
Fundamentals
Return on Equity
21.59%
Trailing 12-Months
Asset Growth
12.54%
Trailing 12-Months
Company Description
Edwards Lifesciences
Incorporated in 1958, California-based Edwards Lifesciences Corp. is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.
---
EW Earnings Call
Q1 2024
0:00 / 0:00
---
EW Net sales Breakdown
64.61% Transcatheter Aortic Valve Replacement
16.64% Surgical Structural Heart
15.46% Critical Care
3.29% Transcatheter Mitral and Tricuspid Therapies
---
EW Stock 12 Months Forecast
Average Price Target
$95.80
▲(13.15% Upside)
Technical Analysis
Best Analysts Covering EW
1 Year
1 Year Success Rate
23/32 ratings generated profit
1 Year Average Return
+19.12%
reiterated a buy rating 23 days ago
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 71.88% of your transactions generating a profit, with an average return of +19.12% per trade.
---